Luminex Shares Surge 30 Percent as Revenue Climbs 23 Percent and Firm Swings to Profit | GenomeWeb
NEW YORK (GenomeWeb News) — Luminex today said fourth-quarter revenue increased 23 percent as R&D spending rose 43 percent as it swung to a profit.
 
News of the earnings caused shares in the company to surge 30 percent, or $3.76, to $16.49 in early-afternoon trading today.
 
Total receipts for the three months ended Dec. 31, 2006, increased to $14.2 million from $11.6 million year over year.
 
R&D spending increased to $2.3 million from $1.6 million year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.